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p75NTR-dependent activation of NF-kB regulates
microRNA-503 transcription and pericyte–
endothelial crosstalk in diabetes after limb
ischaemia
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The communication between vascular endothelial cells (ECs) and pericytes in the micro-
vasculature is fundamental for vascular growth and homeostasis; however, these processes
are disrupted by diabetes. Here we show that modulation of p75NTR expression in ECs
exposed to high glucose activates transcription of miR-503, which negatively affects pericyte
function. p75NTR activates NF-kB to bind the miR-503 promoter and upregulate miR-503
expression in ECs. NF-kB further induces activation of Rho kinase and shedding of endothelial
microparticles carrying miR-503, which transfer miR-503 from ECs to vascular pericytes. The
integrin-mediated uptake of miR-503 in the recipient pericytes reduces expression of EFNB2
and VEGFA, resulting in impaired migration and proliferation. We conﬁrm operation of the
above mechanisms in mouse models of diabetes, in which EC-derived miR-503 reduces
pericyte coverage of capillaries, increased permeability and impaired post-ischaemic angio-
genesis in limb muscles. Collectively, our data demonstrate that miR-503 regulates pericyte–
endothelial crosstalk in microvascular diabetic complications.
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H
yperglycaemia causes vascular endothelial cell (EC)
dysfunction, microvascular rarefaction and macrovascular
disease during diabetes1. Peripheral vascular compli-
cations, including non-healing skin ulcers, frequently have
deleterious outcomes resulting in foot or lower limb ampu-
tation in diabetic patients. This in turn is associated with the high
rates of morbidity and mortality, at a tremendous cost to the
national health care2. The evolution of ischaemic disease in
diabetic patients is worsened because of impairment of the
reparative angiogenesis process3. ECs represent major sites of
hyperglycaemic damage due to their ability to readily accumulate
D-glucose. Thus, altered intracellular signalling under diabetes
induces a phenotypic switch from the normal quiescent proﬁle to
a more apoptotic, pro-inﬂammatory or antiangiogenic phenotype
of ECs4. The dysfunction, degeneration and loss of vascular
pericytes in diabetes additionally contribute to microvascular
complications in the retina5, kidney6 and skeletal muscles7. Yet, it
still remains a challenge to deﬁne the master regulators of gene
expression in the vasculature during diabetes. Nevertheless, an
emerging picture is already developing, whereby microRNAs
(miRNAs) are deemed to be critical regulators of this process.
MiRNAs are small non-coding RNAs ofB22 nucleotides, which
mediate the degradation of target mRNAs or their translational
arrest through base pairing with the target gene 30-untranslated
regions (UTR)8. The characterization of miRNAs in vascular cells
has opened novel therapeutic options for the prevention of
vascular and cardiovascular diseases (reviewed in ref. 9). We have
previously revealed the signiﬁcance of miR-503 in diabetes-
associated endothelial dysfunction and impaired post-ischaemic
vascular repair10. The expression of miR-503 is upregulated in
cultured ECs under conditions mimicking hyperglycaemia and
ischaemia. Moreover, miR-503 expression is upregulated in the
ischaemic limb muscles of diabetic mice and patients. Further,
antagonizing miR-503 in mice improved the post-ischaemic
reparative neovascularization and restores the expression of target
genes in the diabetic and ischaemic limb muscles10. However, the
transcriptional regulation of miR-503 by diabetes and ischaemia
has not been investigated yet. Similarly to miR-503, we have
also identiﬁed that the p75 neurotrophin receptor (p75NTR) is
induced in microvascular ECs in association with diabetes and
limb ischaemia, and that it impairs angiogenesis in vitro
and in vivo11,12. The p75NTR is a multifunctional membrane
receptor belonging to the tumour-necrosis factor receptor
superfamily, originally identiﬁed as a receptor for nerve growth
factor13. The function of p75NTR varies considerably depending
on the cellular milieu in which this receptor is expressed. P75NTR
can be activated in both a ligand-dependent and -independent
manner; therefore, its signalling proceeds via recruitment and
release of the cytoplasmic effectors to and from its intracellular
domain. The activation of p75NTR can lead to activation of three
main pathways: NF-kB pathway, apoptotic signalling through
caspase activation and via the small GTPase RhoA13.
Of further relevance for this study, we have previously shown
that increased p75NTR expression increases shedding of micro-
particles (MPs) from the cultured ECs11. Recent studies have also
identiﬁed that miRNAs are released from cells into different types
of extracellular vesicles (EVs), such as exosomes (30–100 nm) or
MPs (100 nm–1 mm), which circulate within the peripheral
blood14–16. The circulating EVs have been proposed to serve as
the signalling molecules and mediators of the intercellular
communication17. In line with this hypothesis, EVs released
from cells are able to alter gene expression and functional
behaviour in recipient cells by transferring their miRNA
content14–16.
ECs and pericytes establish a cellular crosstalk in the
microvasculature, which is fundamental for the regulation of
angiogenesis, microvascular stabilization and permeability, but is
disrupted under diabetes18. However, it has not yet been
demonstrated whether the trafﬁcking of miRNAs in the MPs
from diabetic ECs can inﬂuence proximate cells, and in particular
neighbouring vascular pericytes.
Here we provide evidence that upregulation of miR-503
through p75NTR-dependent activation of NF-kB in ECs impairs
endothelial function and angiogenesis. Moreover, we demon-
strate that the antiangiogenic properties of miR-503 are conferred
by the production and transfer of endothelial MPs carrying
miR-503 into recipient pericytes, where miR-503 further
suppresses the endothelial–pericyte crosstalk by targeting EFNB2
and VEGFA. The passage of miR-503 from ECs to pericytes,
where miR-503 is expressed in lower amount compared with ECs
and is not transcribed or processed under diabetes and ischaemia,
yet it is in part regulated by b3-integrin antagonists. Moreover,
we found that transfer of miR-503 occurs also in vivo from ECs to
pericytes and it increases vascular permeability during diabetic
ischaemia.
Results
The p75NTR receptor regulates miR-503 expression. We have
previously reported minimal or no expression of p75NTR in cul-
tured human umbilical vein ECs (HUVECs), human micro-
vascular ECs (HMVECs) under basal conditions and in the
capillaries of limb muscles of healthy mice11,12. In diabetes,
especially when associated with tissue ischaemia or injury, the
expression of p75NTR increases in the microvascular ECs11,12
(Supplementary Fig. 1). Exposure of cells to high D-glucose
concentrations (HG) and culture in low-growth-factor medium,
conditions that mimic diabetes and ischaemia in vitro (L-Glucose
as an osmotic control; Cont), increases p75NTR mRNA and
protein expression in both HUVECs (Fig. 1a,b) and HMVECs
(Supplementary Fig. 2A,B). The p75NTR expression is not
regulated by the osmotic pressure (normal glucose (NG) versus
Cont, Fig. 1a,b and Supplementary Fig. 2A,B).
To explore which miRNAs are regulated by p75NTR in ECs,
a miRNA microarray was performed in HUVECs overexpressing
p75NTR (adenoviral vector p75NTR: Ad.p75; control: Ad.Null;
Supplementary Fig. 2C) and the top-ranked miRNAs
(Supplementary Fig. 2D) were validated using qPCR. This
resulted in an increased expression of miR-503, miR-30-c2*,
miR-183* and miR-198, with miR-503 being the most upregu-
lated (Fig. 1c). Overexpression of p75NTR further induced the
expression of miR-503 precursor (pri-miR-503; Fig. 1d). In
addition, the expression of miR-503 increased in HUVECs
exposed to HG, with this response being prevented on knock-
down of p75NTR by short interfering RNA (Fig. 1e and
Supplementary Fig. 3A,B).
To better clarify the link between miR-503 and p75NTR, we
analysed the functional effect of miR-503 inhibition in the
p75NTR-overexpressing HUVECs. Inhibition of miR-503 was
achieved by using adenovirus-decoy.miR-503 (Ad.decoy503)
vector, as before10. In the p75NTR-transduced ECs the
proliferation capacities and network formation on Matrigel
were impaired11, yet these defects could be corrected on
addition of Ad.decoy503 (Supplementary Fig. 3C,D, respectively).
In vivo regulation of miR-503 by p75NTR. We previously
demonstrated that diabetic p75NTR knockout mice (p75KO),
with surgically induced limb ischaemia, show improved post-
ischaemic angiogenesis and blood ﬂow recovery in comparison
with the diabetic wild-type (WT) mice19. Conversely, local
adenovirus-mediated overexpression of p75NTR impairs post-
ischaemic recovery in non-diabetic WT mice (compared with
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non-diabetic WT mice injected with Ad.Null)11. The miR-503
expression was increased in the ischaemic muscles of diabetic WT
mice, but not in diabetic p75KO mice (Fig. 2a). Moreover, Ad.p75
increased miR-503 expression in non-diabetic WT, with this
response being blunted by simultaneous injection of Ad.decoy503
(Fig. 2b). Importantly, Ad.decoy503 reduced the negative impact
of Ad.p75 (versus Ad.Null) on post-ischaemic recovery by
improving reperfusion (Fig. 2c), increasing the capillary and
arteriole densities in the ischaemic muscles (Fig. 2d,e), and
reducing the number of necrotic toes (Supplementary Fig. 4A).
Finally, the analysis of expression of CDC25A and CCNE1,
previously identiﬁed target genes of miR-503 (ref. 10), conﬁrmed
that Ad.p75 injection alone inhibits their mRNA level; however,
this effect was reverted by the co-injection of Ad.p75 and
Ad.decoy503 (Supplementary Fig. 4B,C). These results conﬁrmed
target gene regulation by miR-503, as previously published in the
diabetic mouse model of limb ischaemia10.
NF-jB p65-dependent transactivation of miR-503. Bioinfor-
matics analysis of miRNAs upregulated by p75NTR has revealed
enrichment for miRNAs transcribed by NF-kB. In particular,
miR-30c-2* (ref. 20), miR-198 (ref. 21) and miR-183* (ref. 22)
were previously identiﬁed as NF-kB targets. In line with this, we
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Figure 1 | p75NTR regulates miR-503 expression. (a) HUVECs were
exposed to high glucose (HG), cultured in normal glucose (NG) or osmotic
control (Cont; L-Glucose) conditions for 24 h, and p75NTR expression was
analysed using qPCR. **Po0.01 versus NG or Cont (n¼ 3). (b)
Representative western blot images and protein quantiﬁcation of p75NTR
and Tubulin expression in total cell extracts. **Po0.01 versus NG or Cont
(n¼ 3). (c) Microarray data validation using qPCR. HUVECs were
transduced with Ad.Null or Ad.p75 and qPCR was carried out to measure the
expression of top-ranked miRNAs. (d) Expression of precursor and mature
miR-503 for c,d; *Po0.05, **Po0.01 versus Ad.Null (n¼ 3). (e) Relative
expression of miR-503 in HUVECs transfected with scrambled oligos (scr
oligos) or short interfering RNA (siRNA)-p75 oligos and then cultured in
Cont or HG for 24 h. **Po0.01 (n¼ 5). Unpaired two-tailed Student’s t-test
or Mann–Whitney nonparametric test was applied. Differences among
groups were analysed using two-way analysis of variance followed by
Bonferroni post hoc test. All values are mean±s.e.m. of three independent
experiments.
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Figure 2 | In vivo regulation of miR-503 by p75NTR. (a) Relative
expression of miR-503 in ischaemic muscle (3 days post ischaemia) of
diabetic and non-diabetic WTand p75KO mice (n¼ 6 per group); *Po0.05
versus WT Non Diab; #Po0.05 versus WT Diab. (b) Relative expression of
miR-503 in ischaemic adductors of non-diabetic mice injected with Ad.p75,
Ad.Null or Ad.p75 and Ad.decoy503 together (n¼6 per group). Ad.Null was
also given to singly injected mice to equalize the virus quantity. (c) Line
graph shows the time course of post-ischaemic foot blood ﬂow recovery in
mice (calculated as the ratio between ischaemic and contralateral foot
blood ﬂow; n¼ 12 per group). Representative colour laser Doppler images
are taken at 14 days post ischaemia. (d,e) Column graphs show capillary
and small arteriole (diametero50mm) densities in ischaemic adductors of
mice at 21 days post ischaemia (n¼ 6 per group). For b–e, *Po0.05 versus
Ad.Null; #Po0.05 versus Ad.p75. Unpaired two-tailed Student’s t-test or
Mann–Whitney nonparametric test was applied. All values are
mean±s.e.m. of three independent experiments.
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tested whether NF-kB could also mediate transcription of
miR-503 in response to increased p75NTR. We thus performed
sequence analysis of the human miR-503 hypothetical promoter
at chromosome X (5,000-bp region spanning the transcription
starting site (TSS) in the genomic location ChrX:133,681,808
(ref. 23)), and identiﬁed a putative binding site for NF-kB p65
at  3,480 bp upstream of the TSS. Interestingly, both p75NTR
overexpression and HG induced the nuclear translocation of
NF-kB p65 subunit in ECs (Fig. 3a). ChIP assay conﬁrmed the
binding of NF-kB p65 to the IKBa promoter (positive control for
NF-kB translocation, Fig. 3b). Further ChIP assays were carried
out to investigate whether NF-kB p65 binds to the promoter
regions of miR-503. Under HG, or after p75NTR overexpression
(Ad.p75), we observed an increased binding of NF-kB p65 to the
miR-503 promoter compared with L-Glucose or Ad.Null,
respectively (Fig. 3c). Trimethylation of histone H3 at lysine
4 (H3K4me3) positively correlates with transcriptional activation
of gene expression24. Accordingly, we detected an enrichment of
H3K4me3 at the TSS of the miR-503 promoter in ECs infected
with Ad.p75 or exposed to HG in comparison with respective
controls (Fig. 3d). Lastly, p75NTR overexpression or HG
treatment in ECs induced a signiﬁcant upregulation in
luciferase activity of the reporter construct containing NF-kB-
binding site within miR-503 promoter sequence. Mutation of a
putative NF-kB-binding site prevented this upregulation of
luciferase activity under the above conditions, thus showing
that binding of NF-kB results in miR-503 transcription (Fig. 3e).
dnIKK2 restores angiogenesis in diabetic ischaemic mice. To
further validate the role of NF-kB in regulating miR-503 tran-
scription in response to HG or p75NTR overexpression, we used a
loss-of-function approach. In particular, we asked whether a
dominant-negative form of IkB kinase 2 (dnIKK2)25, a kinase that
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Figure 3 | NF-jB p65 binds miR-503 promoter and regulates its transcription. (a) HUVECs were treated with HG (control: L-Glucose) or transduced
with Ad.p75 (control: Ad.Null). Representative western blot images and protein quantiﬁcation of NF-kB p65, Tubulin and Laminin in nuclear and
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is an upstream activator of NF-kB, interferes with the expression
of miR-503. In cultured ECs, Ad.dnIKK2 reduced the pri-
miR-503 and mature miR-503 expression, which were previously
increased by Ad.p75 (Fig. 4a) or HG (Supplementary Fig. 5A).
In addition, local delivery of Ad.dnIKK2 dramatically reduced
miR-503 expression in the ischaemic limb muscles of diabetic
mice (Fig. 4b). Moreover, Ad.dnIKK2 rescued the blood ﬂow
recovery (Fig. 4c and Supplementary Fig. 5B), increasing the
capillary and arteriole densities in ischaemic limb muscles of
diabetic mice (Fig. 4d,e, respectively), and reduced the number
of necrotic toes (Supplementary Fig. 5C). These positive effects
of Ad.dnIKK2 on vascularization were abolished by the
simultaneous overexpression of miR-503 (by adenovirus
carrying miR-503; Ad.miR-503; Fig. 4c–e and Supplementary
Fig. 5B,C). Taken together, the above evidence suggests that
regulation of NF-kB has a strong impact on post-ischaemic
vascularization in diabetic mice via the regulation of miR-503
expression.
Mechanism of MPs-miR-503 release from ECs. Following
p75NTR overexpression, the release of MPs carrying miR-503
from the cultured ECs increased (Fig. 5a). To this end, we also
found that condition that mimics diabetes and ischaemia in vitro
(HG in low-growth-factor medium) increased the expression
of miR-503 within MPs (Fig. 5a). In addition, miR-503 was
present in the MPs from the plasma of diabetic ischaemic mice
and non-diabetic ischaemic mice following adenovirus-mediated
overexpression of p75NTR (Fig. 5b). Transmission electron
microscopy on HUVECs transduced with Ad.Null or Ad.p75
conﬁrmed the shedding of MPs by a membrane-blebbing process,
which is typical of MPs (Fig. 5c). The MPs collected from the
medium showed a heterogeneous pattern of particles, withB70%
of MPs being 200–500 nm in size (Supplementary Fig. 6A). Then,
we used ﬂow cytometry to analyse and quantify MPs, and we
showed that p75NTR increased the release of a well-deﬁned
population of HUVEC-derived MPs, which were expressing
Annexin-V (AnnVPos) on their extracellular surface (Supple-
mentary Fig. 6B). Further analysis of expression of vascular
miRNAs showed that miR-126, miR-143 and miR-145 are not
upregulated in the ECs nor released into the endothelial MPs
following overexpression of p75NTR (Supplementary Fig. 6C,D).
Next, we examined the possible mechanism of p75NTR-related
release of endothelial MPs. Previous studies have identiﬁed the
role of Rho kinases (ROCK)26,27 and NF-kB pathways28 in the
biogenesis of MPs and their release in different cellular contexts.
Following p75NTR overexpression, either the inhibitors of ROCK
(Y27632 or HA-1077) or NF-kB (dnIKK2) decreased the release
of MPs (Fig. 5d). The apoptotic membrane blebbing, a core event
in the shedding of MPs, can also be induced by caspase-
3-mediated activation of ROCK and subsequent myosin light-
chain (MLC) phosphorylation29. Since p75NTR overexpression
induces caspase-3-dependent apoptosis in ECs11, we analysed the
regulation of caspase-3 activity by NF-kB. Transduction of
HUVECs with Ad.dnIKK2 to inhibit NF-kB blocked p75NTR-
mediated caspase-3 activation (Fig. 5e). Overexpression of a
truncated form of p75NTR (p75NTR cytoplasmatic domain,
p75CD, missing the death domain and thus not able to activate
caspase-3 (ref. 30)) failed to promote the release of endothelial
MPs (Fig. 5d,e). In addition, inhibition of NF-kB decreased
p75NTR-mediated phosphorylation of MLC2 and myosin
phosphatase target protein (MYPT1), another ROCK sub-
strate31, with an effect comparable to treatment with ROCK
inhibitors, Y27632 and HA-1077 (Fig. 5f). Taken together, these
results demonstrate that NF-kB activation is a major determinant
in caspase-3/ROCK-mediated release of MPs on activation of
p75NTR. Similarly to Ad.p75, the exposure to HG has induced
shedding of MPs in HUVECs, and this response was inhibited by
Y27632, HA-1077 or Ad.dnIKK2 (Supplementary Fig. 6E,F).
Moreover, EC apoptosis was reduced by Ad.dnIKK2 (Supple-
mentary Fig. 6G).
miR-503 regulates EFNB2 and VEGFA expression in pericytes.
The Targetscan 6.2 algorithm32 predicted EFNB2 and VEGFA to
be the direct targets of miR-503. Accordingly, both targets were
predicted to contain a single conserved binding sequence for
miR-503 in their 30UTRs (Supplementary Fig. 7A). EFNB2
controls interactions between the pericytes and endothelium, and
their motility33. Moreover, pericytes promote survival of ECs
through paracrine VEGFA signalling34. Then, to investigate
whether miR-503 directly binds the 30UTRs of EFNB2 and
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Figure 4 | In vivo NF-jB-dependent transcription of miR-503.
(a) HUVECs were transduced with Ad.Null, Ad.p75 or Ad.dnIKK2, and qPCR
was carried out to measure the expression of pri-miR-503 and mature
miR-503; **Po0.01 versus Ad.Null; #Po0.05, ##Po0.01 versus Ad.p75
(n¼ 3). (b) Relative expression of miR-503 in the ischaemic adductors of
non-diabetic and diabetic mice, which received Ad.Null, Ad.dnIKK2 or
Ad.miR-503 (n¼6 per group). Ad.Null was given to singly injected mice to
equalize the virus quantity. (c) Line graph shows the time course of post-
ischaemic foot blood ﬂow recovery in mice (calculated as the ratio between
ischaemic and contralateral foot blood ﬂow; n¼ 12 per group).
(d,e) Column graphs show capillary and small arteriole (diametero50mm)
densities in the ischaemic adductors of mice at 21 days post-ischaemia
(n¼8 per group). For b–e, *Po0.05 versus Non DiabþAd.Null; #Po0.05
versus DiabþAd.Null; yPo0.05 versus DiabþAd.dnIKK2. Unpaired two-
tailed Student’s t-test or Mann–Whitney nonparametric test was applied.
All values are mean±s.e.m. of three independent experiments.
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VEGFA, we performed a luciferase reporter assay in which
luciferase, the reporter gene, was fused to the WT 30UTRs of
EFNB2 or VEGFA, respectively. Overexpression of miR-503
(Supplementary Fig. 7B) decreased luciferase activity for each of
the putative target genes, whereas mutation of the putative miR-
503-binding site within EFNB2 or VEGFA prevented miR-503-
induced reduction in luciferase activity (Fig. 6a,b). Moreover,
miR-503 overexpression reduced the target gene mRNA
(Supplementary Fig. 7C) and protein levels (Fig. 6c), and the
secretion of VEGFA in cell medium (Fig. 6d). Next, we
investigated the role of miR-503 on the functional properties of
pericytes. Overexpression of miR-503 reduced the proliferative
and migratory capacities of pericytes (Fig. 6e,f). Following
silencing of EFNB2 in pericytes, we observed reduced
proliferation and migration, whereas silencing of VEGFA
reduced only the migration of pericytes (Fig. 6e,f). Finally, we
investigated whether EFNB2 and VEGFA are required for
miR-503-induced regulation of migration and proliferation in
pericytes. To this end, miR-503 was overexpressed in the
presence of EFNB2 or VEGFA cDNA, which lacked parts of the
*
# #
#
*
#
**
**
*
10
8
6
4
2
0
6
m
iR
-5
03
re
la
tiv
e
 e
xp
re
ss
io
n
m
iR
-5
03
re
la
tiv
e
 e
xp
re
ss
io
n
4
2
0
*
**
##
## ##
- 140
2.0 5
4
3
2
1
0
1.5
1.0
0.5
0.0
- 18
- 18
- 55
- 140
**
##
## ##
HUVEC MPs Plasma MPs
Caspase 3 assay
R
el
at
ive
 lu
ci
fe
ra
se
 u
n
its
Pr
ot
ei
n
re
la
tiv
e
 e
xp
re
ss
io
n
Pr
ot
ei
n
re
la
tiv
e
 e
xp
re
ss
io
n
AV
po
s  
M
Ps
/u
l
HUVEC MPs1,500
1,000
500
0
Ad
.Nu
ll
Ad
.Nu
ll
Ad
.Nu
ll
Ad
.p7
5C
D
Ad
.p7
5C
D
Ad
.p7
5
Ad
.p7
5
Ad
.p7
5
Ad
.p7
5+
HA
-10
77
Ad
.p7
5+
HA
Ad
.p7
5+
Y
Ad
.p7
5+
dn
lKK
2
Ad
.p7
5+
Y2
76
32
Ad
.p7
5+
dn
lKK
2
Ad
.p7
5+
ad
.dn
lKK
2
Ad
.Nu
ll
Ad
.p7
5
Ad
.p7
5+
HA
-10
77
Ad
.p7
5+
Y2
76
32
Ad
.p7
5+
dn
lKK
2
Ad
.Nu
ll
Ad
.p7
5
Ad
.p7
5+
HA
-10
77
Ad
.p7
5+
Y2
76
32
Ad
.p7
5+
dn
lKK
2
150,000
100,000
50,000
0
Co
nt HG
Ad
.Nu
ll
Ad
.p7
5
No
n d
iab Dia
b
Isc
h
Dia
b I
sch
Ad
.Nu
ll
Ad
.p7
5
p-MYPT1 (T853)
Total MYPT1
p-MLC2 (T18/S19)
Total MLC2
Tubulin
pMLC2/MLC2pMYPT1/MYPT1
Figure 5 | Mechanism of MP-miR-503 release in endothelial cells. Expression of mature miR-503 in MPs isolated by centrifugation from (a) the
supernatant of HUVECs transduced with Ad.Null or Ad.p75; or exposed to HG versus L-Glucose control (**Po0.01, *Po0.05 versus Cont or Ad.Null; n¼ 3).
(b) From the plasma of non-diabetic, diabetic, non-diabetic ischaemic and diabetic ischaemic mice or ischaemic mice after Ad.Null or Ad.p75 overexpression
(**Po0.01, *Po0.05 versus Non-Diab; *Po0.05 versus Ad.Null, n¼ 8 per group). (c) Transmission electron microscopy showing the shedding of MPs by a
membrane-blebbing process in Ad.Null- (left) and Ad.p75 (middle)-transduced HUVECs; (right) puriﬁed endothelial MPs showing a spheroid shape. Scale
bars, 500nm. (d) Flow cytometric analysis of MPs from HUVECs transduced with the Ad.Null, Ad.p75, Ad.dnIKK2 or treated with Rho kinase inhibitors
Y27632 (10 mM) and HA-1077 (10 mM). (e) Caspase-3 activity in HUVECs transduced with Ad.Null, Ad.p75 or Ad.dnIKK2. (f) Representative western blot
analyses and protein quantiﬁcation of phospho and total MLC2 and MYPT1 in HUVECs transduced with Ad.Null, Ad.p75, Ad.dnIKK2 or treated with Rho
kinase inhibitors Y27632 and HA-1077. For d–f, *Po0.05, **Po0.01 versus Ad.Null, #Po0.05, ##Po0.01 versus Ad.p75 (n¼ 3). Unpaired two-tailed
Student’s t-test or Mann–Whitney nonparametric test was applied. All values are mean±s.e.m. of three independent experiments.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9024
6 NATURE COMMUNICATIONS | 6:8024 | DOI: 10.1038/ncomms9024 |www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
30UTR sequence (DEFNB2 and DVEGFA) containing the binding
sites for the miR-503 (and therefore could not be targeted by
miR-503). The results showed that overexpression of DEFNB2
(Supplementary Fig. 8A,C) or DVEGFA (Supplementary
Fig. 8B,D) has partially restored migration and proliferation
capacities in pericytes.
MPs transport miR-503 from ECs into pericytes. Then, we
investigated whether endothelial MPs containing miR-503 could
transfer miR-503 from ECs into pericytes and thus reduce the
expression of miR-503 target genes in the recipient cells. Under
basal conditions, pericytes express miR-503, although in a lower
amount compared with ECs. However, treatment with HG in
low-growth-factor medium did not increase miR-503 transcrip-
tion (pri-miR-503 levels) or the levels of mature miR-503 in
pericytes (Fig. 7a). Direct incubation of pericytes with the
endothelial MPs carrying miR-503 increased the intracellular
levels of miR-503 in a concentration-dependent manner
(Supplementary Fig. 9A). To then determine whether endothelial
MPs could be transferred into pericytes in a paracrine manner, we
employed a coculture system with HUVECs on top and pericytes
at the bottom, separated by a membrane to prevent direct cell–cell
contact. As noted before, p75NTR overexpression induced the
release of MPs carrying miR-503 in HUVECs (Fig. 5a). HUVECs
were labelled with 3,30-dioctadecyloxacarbocyanine (green ﬂuor-
escence) and transduced with Ad.p75 or Ad.Null. In this coculture
system, green-labelled endothelial MPs were transferred from the
p75NTR-HUVECs into pericytes (Supplementary Fig. 9B) and
increased expression of miR-503 was detected in the pericytes
(Fig. 7b). Consistently, the inhibition of ROCK (by Y27632 or
HA-1077) or NF-kB (dnIKK2), previously shown to decrease the
release of MPs (Fig. 5d), has reduced the transfer of miR-503 into
pericytes exposed to the MPs (Fig. 7c), also suggesting that this
process is mediated by actively formed endothelial MPs. More-
over, transfer of endothelial MPs carrying miR-503 into pericytes
reduced the expression of EFNB2 and VEGFA, whereas use of
ROCK or NF-kB inhibitors has prevented the downregulation of
the two miR-503 target genes (Fig. 7d).
Several studies demonstrated that incorporation of MPs in
target cells required the engagement with integrins35,36. Taking
this into consideration, we have analysed the effect of Eptiﬁbatide,
an antagonist of b3 integrins37, on the uptake of GFP-labelled
MPs by pericytes (Fig. 7e). The uptake of MPs was seen through
the increase of GFP protein in the pericytes and was partially
reduced because of treatment with Eptiﬁbatide (250 mm; Fig. 7e).
Furthermore, using a coculture system described above, we have
demonstrated that treatment with Eptiﬁbatide prevented the
transfer of miR-503 through MPs from ECs into pericytes
(Fig. 7f), preventing the downregulation of target genes, VEGFA
and EFNB2 by miR-503 (Fig. 7f). In conclusion, the crosstalk
between ECs and pericyte MPs could be in part regulated by the
integrin signalling.
The in vivo transfer of miR-503 between ECs and pericytes. On
the basis of our in vitro ﬁndings we additionally explored whether
transfer of miR-503 from ECs into pericytes could repress EFNB2
and VEGFA in vivo. To this aim, ECs and pericytes were sorted
using CD31 and NG2 antibodies, respectively, from the ischaemic
and non-ischaemic limb muscles of diabetic and non-diabetic
mice (Supplementary Fig. 10. In ECs extracted from ischaemic
limbs of diabetic mice, the pri-miR-503 and mature miR-503 are
more expressed in comparison with non-diabetic muscle (Fig. 8a),
whereas diabetes and ischaemia did not increase the transcription
of pri-miR-503 in the pericytes (Fig. 8b). Nonetheless, signiﬁcant
increase of expression of the mature miR-503 is observed in the
pericytes under diabetic ischaemia (Fig. 8b), thus suggesting that
mature miR-503 was likely to be acquired in a paracrine manner
and not produced by the pericytes. In line with this, mRNA levels
of EFNB2 and VEGFA were signiﬁcantly lower in the sorted
pericytes from diabetic muscles following limb ischaemia in
comparison with non-diabetic muscles (Fig. 8c). Reduced EFNB2
expression has been associated with the loss of pericytes, leading
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to excessive vascular permeability33. Therefore, we evaluated the
impact of local miR-503 inhibition (by Ad.decoy503) on vascular
permeability in the ischaemic muscles of diabetic mice, using
Ad-Null-infected ischaemic muscles from non-diabetic mice as
additional reference (Fig. 8d).
Within diabetic ischaemic muscles, there was a substantial
increase in the retention of Evans blue dye, demonstrating an
increased vascular permeability. This could be prevented by local
inhibition of miR-503 (Fig. 8d). Because pericyte coverage often
correlates with vascular permeability38, we have quantiﬁed the
coverage of pericytes in capillaries by NG2 and isolectin-B4 co-
staining. In agreement with the observed increased permeability,
there was a signiﬁcant decrease in the pericyte coverage of the
neovasculature in diabetic ischaemic limb muscles, whereas
decoy503 overexpression has restored pericyte density close to
the ischaemic control (Fig. 8e,f).
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Finally, we employed in situ hybridization to further conﬁrm
the localization of miR-503 in ECs and pericytes in the limb
muscles of diabetic ischaemic mice (Supplementary Fig. 11).
A triple staining was performed using a miR-503 probe, isolectin-
B4 and NG2. Absence of the staining using the scramble sequence
probe shows the success of the protocol with this technique
(Supplementary Fig. 11A). MiR-503 was not detectable in the
non-diabetic controls (Supplementary Fig. 11B), but localized to
ECs, pericytes and myocytes within diabetic ischaemic muscles
(Supplementary Fig. 11C).
Figure 9 presented the proposed mechanism behind the
crosstalk between ECs and pericytes during microvascular
complications of diabetes.
Discussion
Our study provides the ﬁrst insights into the mechanisms of
transcriptional regulation of miR-503 in ECs by diabetes. We
additionally show the ﬁrst evidence of the release and trafﬁcking
of endothelial MPs from ECs into pericytes, thus MP mediated
the transfer of miR-503 during the diabetes-induced vascular
disease. Previously, we deﬁned neurotrophin receptor p75NTR
and miR-503 as independent negative modulators of EC function
and diabetes-induced post-ischaemic reparative neovasculariza-
tion10,11. Here we have further explored and established the
mechanisms that regulate miR-503 expression through p75NTR
activation of NF-kB; associated them with the negative effects
diabetes induces on vascular cells. Moreover, we have
demonstrated that miR-503 can be transferred via endothelial
MPs to produce a negative effect in the neighbouring pericytes.
To our knowledge, this is the very ﬁrst example of a direct
involvement of miR-503 signalling in the endothelial–pericyte
crosstalk under diabetic ischaemia.
Given that the cytoplasmatic domain of p75NTR does not
contain a catalytic motif, the signal mediation depends on the
interaction with cytoplasmic proteins; complex signalling, how-
ever, makes it difﬁcult to formulate a uniﬁed functional model
downstream of this receptor13. We provide mechanistic evidence
that NF-kB plays a primary role in regulating miR-503
transcription in ECs, exposed to HG or overexpressing p75NTR.
Moreover, the activation of NF-kB determines the release of
miR-503 within the endothelial MPs, which can be found in the
extracellular compartment in vitro and in the systemic circulation
of diabetic ischaemic mice. P75NTR mediates nuclear
translocation of the NF-kB p65 subunit to bind the promoter
of miR-503 and induce transcription of miR-503. Moreover,
NF-kB-dependent p75NTR regulation of apoptosis further induces
ROCK activation, leading to blebbing of cellular membrane and
shedding of endothelial MPs. NF-kB activation is sufﬁcient to
control the transcriptional regulation of miR-503 and its release
into MPs. Interestingly, recent in vitro studies have clariﬁed the
involvement of epigenetic mechanisms in the modulation of
glucose-induced gene expression of the key subunit of NF-kB
p65, with subsequent effects on the NF-kB activation39. This
opens up the possibilities for novel integrative approaches to
understand the pathogenesis of diabetic vascular complications.
There is currently a large interest in signalling pathways
operating during EC–pericyte crosstalk18,40; therefore, future
investigation will provide crucial information on the paracrine
molecular mechanisms controlling capillary formation.
We have initially identiﬁed VEGFA and EFNB2 as target genes
of miR-503, and both of these targets are critical for EC–pericyte
crosstalk. Pericytes produce VEGFA, which promotes EC survival
and guides migration and angiogenesis34,41. Ephrin-Eph receptor
signalling plays major roles in ECs but has also been implicated in
mural cell biology. A mural cell-speciﬁc knockout of efnb2
resulted in poor association of vascular smooth muscle cells and
pericytes within vessels of different sizes33. Moreover, efnb2 is a
critical mediator of endothelial-to-pericyte assembly during the
postnatal vascular remodelling42.
Despite the tight association between the ECs and pericytes in
microcirculation, and their interdependent nature, the mechan-
isms of EC–pericyte interaction in diabetes are largely unknown.
However, a striking correlation exists between the pericyte
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values are mean±s.e.m. of three independent experiments.
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coverage and microvessel stabilization43 as well as the micro-
vascular permeability. Several studies demonstrated that pericyte
deﬁciency causes increased vessel permeability (for example, in
PDGF-B/PDGFR-b mutant mice), the degree of which correlated
directly with density of pericytes44,45. Hence, pericytes regulate
EC-to-cell junctions and EC behaviour46, which confers these
mural cells with a greater biological relevance than being just
supportive cells.
In addition, the decrease of pericyte coverage in the micro-
circulation precedes capillary loss as already described in diabetic
retinopathy47 and in the pancreatic islet48. In line with this, we
can hypothesize that loss of ECs during diabetic ischaemia in limb
muscles could be in part a consequence of the lost EC–pericyte
interaction.
Here we demonstrated that decrease in pericyte coverage
correlated with increased permeability in limb muscles of diabetic
ischaemic mice. Overexpression of decoy503 in the ischaemic
limb muscles of diabetic mice has restored pericyte coverage close
to the ischaemic control. Overall, we propose that miR-503
upregulation within the ECs affects the pericyte functionality and
in vivo coverage, which correlates with the increased vascular
permeability in a diabetic ischaemic mouse model.
Beside soluble factors, receptor-mediated events and direct
cell-to-cell contact, more recent studies have suggested that cells
may also communicate by EVs49. Two distinct processes of EV
release from the cells have been described so far: (1) they may
derive from the endosomal membranes that are extruded from
the cell surface of activated cells as exosomes50 and, alternatively,
(2) EVs may take origin by direct shedding from the cell plasma
membrane as MPs. The MPs released from ECs are named
endothelial MPs and are identiﬁed by carrying EC protein
markers and by binding to the apoptosis marker Annexin-V
(ref. 17). Endothelial MPs are regarded as a possible biomarker of
EC dysfunction, and their circulating numbers are elevated in
diabetic patients with endothelial dysfunction51. We have
previously demonstrated that in ECs p75NTR promotes the
release of endothelial MPs11. Now, we provide new evidence that
MPs carrying miR-503 are secreted from diabetic ECs and can
transfer miR-503 into the neighbouring pericytes, thus
modulating gene expression and their biological phenotype.
Our data show that transcription of pri-miR-503 is not increased
in the pericytes under ischaemic condition in diabetic mice.
Moreover, in our in vivo experiment, we detected only the mature
form of miR-503 in the pericytes, which might be reconciled
with a direct transfer of mature miR-503 from the endothelial
MPs into pericytes. Then, our study extends these ﬁnd-
ings by establishing that endothelial MPs carrying miR-503
interfere with EFNB2 and VEGFA expression in pericytes, further
blocking post-ischaemic angiogenesis and vascular integrity
under diabetes.
The discovery of an endothelial MP-mediated delivery of
miR-503 into pericytes raises intriguing possibilities to better
understand the mechanisms behind various models of vascular
cell-to-cell communications.
One of the most important and unknown aspects of MP
function concerns how MPs, on being shed from ECs, target
recipient cells and transfer their cargo. Potential mechanisms
previously described have shown that MPs target their recipient
cells through interaction with integrins35 and phosphatidylserine
receptors52. Currently, it is unclear whether speciﬁc receptors on
ECs or pericytes take up MP–miRNA complex and which
mechanisms are at play to load functional miRNAs into MPs.
In this study, we have demonstrated that the uptake of
endothelial MPs into pericytes is partially mediated by
b3 integrins. Integrins are expressed not only in ECs but also
on the surface of pericytes53. Being that endothelial MPs express
the adhesion molecules of their parent cells54, the inhibition of
their uptake by pericytes using Eptiﬁbatide can be attributed to
the blockade of b3 integrins either on MP and/or pericyte surface.
Future studies are required to demonstrate the involvement and
to delineate the speciﬁc mechanisms behind MP–miRNA
communication in vivo.
In conclusion, our data demonstrate a novel mechanism in
diabetic ischaemia, involving coordinated expression of p75NTR
and regulation of miR-503 in ECs, and thus leading to impaired
function of pericytes following uptake of the endothelial MPs
carrying miR-503.
Methods
Cells and cell culture. HUVECs and HMVECs (both from Lonza) were grown in
EGM-2 (EBM-2 medium supplemented with growth factors and normal 5mM
D-Glucose, NG) and 2% fetal bovine serum (FBS; Lonza). To mimic diabetes and
ischaemia in vitro, the ECs were maintained in EBM-2 (growth factor-free
medium) with 2% FBS and 25mM D-glucose (HG). L-Glucose was used as an
osmotic Cont at the concentration of 25mM. HUVECs were used between P2 and
P6 passages. HA-1077 or Y27632 (Sigma) have been used at concentration of
10 mM; Eptiﬁbatide (Sigma) has been used at concentration of 250 mM. HEK293T
cells (ATCC, CRL-11268) were cultured in D-MEM with 10% FBS (Life Tech-
nologies). Pericytes were grown on ﬁbronectin (10mgml 1)-coated plates and
maintained in EGM-2 with 2% FBS.
Pericyte isolation. Pericyte progenitor cells were isolated from vein leftovers of
patients undergoing coronary artery bypass graft surgery or varicose vein removal,
as previously described55. In brief, saphenous veins were carefully dissected from
surrounding tissues using a sterile scalpel and then thoroughly washed in PBS.
Veins were manually minced before 4-h incubation with 3.7mgml 1 Liberase
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Figure 9 | Proposed mechanism of crosstalk between ECs and pericytes during microvascular diabetic complications. p75NTR-dependent activation of
NF-kB regulates miR-503 transcription in hyperglycemic ECs and the release of miR-503 in the extracellular compartment within microparticles.
Microparticles carrying miR-503 are secreted from the diabetic ECs and can be transferred into neighbouring pericytes to subsequently modulate vessel
permeability and angiogenesis through miR-503 target genes, VEGFA and EFNB2.
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2 (Roche) and ﬁltered passing the cell suspension through a 30-mm cell strainer.
Cells were depleted for ECs with anti-CD31-conjugated beads (Miltenyi),
according to the manufacturer’s instruction. The remaining cells were puriﬁed by
selecting CD34þ cells by anti-CD34 beads (Miltenyi). Target cells were then
plated on ﬁbronectin (10 mgml 1)-coated plates in presence of differentiation
medium (EGM-2—2% FBS, Lonza). Adherent colonies were passaged to new
culture dishes once they reached 60–70% conﬂuence and frozen stocks generated
after Passage 2 (P2) for the experiments shown in this publication. Trypsin-EDTA
(Life Technologies) was utilized to detach cells from the growth substrate.
Plasmid cloning. To clone EFNB2 or VEGFA, cDNAs, which lacked parts of the
30UTR sequence and could not be targeted by miR-503 (EFNA2D or VEGFAD),
EFNA2 (NCBI accession: NM_004093) and VEGFA cDNA (NCBI accession:
NM_001025366), were excised from pCMV6-XL4 (Origene) using NotI/XbaI or
NotI/SmaI, respectively and cloned in pcDNA3.1 using standard techniques. Thus,
the last 2,834 bps of EFNA2 30UTR or 1,705 bps of VEGFA 30UTR, encompassing
miR-503-binding sites, were deleted. Plasmids were transfected using Lipofecta-
mine 3,000 (Invitrogen) according to the manufacturer’s instructions.
Cell transfection, recombinant adenovirus and cell functional assay.
Lipofectamine RNAiMAX (Invitrogen) was used to transfect HUVECs, HEK293T
or pericytes with pre-miR-503, pre-miR-control (50 nM ﬁnal concentration) or
with short interfering RNA targeting p75NTR, EFNB2 or VEGFA, according to the
manufacturer’s instructions. Adenoviral particles of human p75NTR (ref. 11), Null,
decoy503 (ref. 56), dnIKK2 (ref. 25) and miR-503 are produced and used as
described in ref. 56. The following functional assays were performed:
5-bromodeoxyuridine incorporation assay using Cell Proliferation colorimetric
assay (Roche); Caspase-activity assay using CaspaseGlo assay (Promega); migration
assay and endothelial barrier function were performed using ECIS machine as
described below. Matrigel assay with HUVECs was performed as previously
described using BD Matrigel Basement Membrane Matrix (BD Biosciences)56.
RNA extraction and quantitative real-time analysis. Total RNA was extracted
using the miReasy kit (Qiagen). Real-time quantiﬁcation to measure miRNAs was
performed with the TaqMan miRNA reverse transcription kit and miRNA assay
(miR-503 cat #001048, miR-183* cat#002270, miR-30c-2* cat#002110, miR-198
cat#002273, miR-30b* cat#002129, miR-658 cat#001513, miR-665 cat#002681,
miR-371-5p cat#000559 and pri-miR-503 cat#Hs 03304160_pri; Applied Biosys-
tems) using Lightcycler 480 (Roche). miRNA expression was normalized to the U6
small nucleolar RNA. For mRNA analysis, cDNA was ampliﬁed by quantitative
real-time PCR (qPCR) and normalized to 18S ribosomal RNA. Each reaction was
performed in triplicate. Quantiﬁcation was performed by the 2DDCt method57.
qPCR was used to measure p75NTR, EFNB2, VEGFA and 18S rRNA. Primers are
predesigned from Sigma (KiCqStart Primers).
Characterization and analysis of MPs. MPs were puriﬁed from cell culture media
from ECs and from platelet-free plasma as previously described11. Brieﬂy,
conﬂuent monolayers of HUVECs were grown and the supernatant was collected
and pre-cleared by centrifugation at 1,500g for 15min at 4 C to remove cell debris.
To pellet the extracellular particles (size,o1 mm), the supernatant was centrifuged
at 20,500g for 1 h at 4 C. The supernatant was removed and discarded, and the
pelleted particles were washed with ice-cold PBS and repelleted by centrifugation at
20,500g for 1 h at 4 C. Finally, the supernatant was removed and discarded, and
the pelleted vesicles were resuspended in 700 ml Qiazol (Qiagen) for RNA isolation
using the miRNeasy kit (Qiagen) following the instructions provided by the
manufacturer or in EBM-2 for other experiments. For ﬂow cytometry analysis,
isolated extracellular particles were stained with an Annexin-V or p75NTR antibody
(BD Biosciences) and analysed by FACS58 with the FACSDiva software
(BD Biosciences) on a FACS Canto II (BD Biosciences).
miRNA array. Total RNA was extracted by using TRIzol (Invitrogen) according to
the manufacturer’s instructions. Total RNAs (2.5 mg) were labelled with either Hy3
or Hy5, following the manufacturer’s protocol (miRCURY LNA microRNA Array
Power labelling kit, Exiqon). Two-colour hybridization was carried out at 53 C for
16 h using miRCURY LNA microRNA Arrays (miRBase v.10.0, Exiqon). Hybri-
dization and washing steps were performed on the HS 400 PRO hybridization
station (Tecan). The signal intensities were acquired by scanning the arrays on the
GenePix 4,100-A microarray scanner (Molecular Devices, GenePix Pro 6.0.1.25
software). The obtained data were analysed by using the Limma package (Smyth,
G.K. 2005) from the Bioconductor Project (Bioconductor 2.5 on R 2.10),
performing background correction (normexp, cutoff¼ 10) and within-array nor-
malization (global LOESS) as well as between-array normalization (scale method).
Differential expression and statistical signiﬁcance were assessed by applying linear
model ﬁt and empirical Bayes method (lmFit, eBayes). The default table of Limma
is ranked by B-statistics (B), closely related to the adjusted P value. The B-statistic
used for this analysis is the log-odds that gene is differentially expressed and it is
automatically adjusted for multiple testing by assuming that 1% of the genes are
expected to be differentially expressed.
ChIP. ChIPs were performed with conﬂuent 15-cm tissue culture plates of
HUVECs (Lonza, 2 106 cells per condition). Cells were crosslinked for 10min
with formaldehyde (ﬁnal concentration¼ 1%). Glycine was added to a ﬁnal con-
centration of 0.125M and incubated for 5min. Cells were washed 2 with PBS
and subsequently lysed in Chip Lysis Buffer (10ml, 100mM NaCl, 0.5% SDS,
5mM EDTA, 50mM Tris-HCl pH 8.1, 0.2% NaN3) supplemented with protease
inhibitors and complete EDTA-free tablet. Cells were pelleted (2,100 r.p.m., 4 C,
6min) and resupsended in 300 ml of IP-dillution buffer (two parts ChIP lysis buffer
and one part Triton dilution buffer: 100mM NaCl, 5% Triton X-100, 5mM EDTA,
100mM Tris-HCl pH 8.6, 0.2% NaN3). Chromatin was sheared (3 600 0ON/
300 0OFF) by sonication (Bioruptor UCD-200 ultrasound sonicator, Diagenode),
resulting in DNA fragments between 200 and 500 bp in size. After centrifugation
(14,000g, 15min, 4 C), between 20 and 50ml of each sample was separated for de-
crosslinking, diluted to 100ml in ChIP elution buffer (1% SDS, 100mM NaHCO3
and proteinase K) and left at 65 C overnight to reverse crosslink for checking the
DNA shearing. If sheared DNA was of the right size, 1% of chromatin sample was
kept as Input. Chromatin was diluted to 200 mgml 1 (for transcription factors) or
50 mgml 1 (for histone modiﬁcations) concentration in the IP-dilution buffer.
Immunoprecipitation was performed in 1ml volume and 3–5 mg of test or control
IgG antibody was added to the diluted chromatin and incubated overnight at 4 C.
The following day, immunocomplexes were collected with puriﬁed protein
A-magnetic beads (Invitrogen) for 3 h at 4 C with rotation. Beads were extensively
washed 2 in low salt (150mM NaCl, 1% Triton X-100, 0.1% SDS, 2mM EDTA
pH 8.0, 20mM Tris-HCl pH 8.0) followed by 1 in high-salt buffer (500mM
NaCl, 1% Triton X-100, 0.1% SDS, 2mM EDTA pH 8.0, 20mM Tris-HCl pH 8.0)
and eluted with 120 ml of elution buffer (1% SDS, 0.1M NaH2CO3) and proteinase
K (1 mgml 1) at 65 C overnight to reverse crosslinking. Associated DNA was then
puriﬁed by extraction using the QIAQuick qPCR kit (Qiagen). qPCR was used to
determine recovery of speciﬁc DNA fragments (primers in Supplementary
Table 1). Within each ChIP experiment, a negative control ChIP was performed
using 5 mg of polyclonal rabbit anti-mouse immunoglobulin (IgG).
Luciferase assays. For transcriptional reporter assays, HUVEC cells were
transfected with p75NTR proximal promoter or miR-503 promoter (Switchgear
Genomics) constructs using GenJet In Vitro DNA Transfection Reagent (Signa-
Gen), and, 24 h later, cells were exposed to L-Glucose or D-Glucose or transduced
with Ad.p75 (Ad.Null as control) for 24 h and lysed using buffer supplied with the
Dual-Luciferase Reporter Assay System (Promega). Mutated plasmids were
generated using GeneTailor Mutagenesis system kit (Invitrogen). To investigate
whether miR-503 directly regulates VEGFA, and EFNB2 expression, portions of
the 30UTR of these potentials target genes were inserted downstream of a luciferase
open reading frame (pLUC). VEGFA 30UTR (S204537) and EFNB2 30UTR
(S213182) vectors were purchased from SwitchGear Genomics. Vectors in which
ﬁve nucleotide mutations were inserted in the 30UTR sequences (VEGFA: 293–299;
EFNB2: 1,126–1,132) complementary to the miR-503 ‘seed’ sequence were pre-
pared using the GeneTailor kit (Invitrogen). Primers are listed in Supplementary
Table 1. Luciferase constructs were transfected into HEK293T cells together with
either pre-miR-503 or a scrambled oligonucleotide sequence (control). Cells were
cultured for 48 h and assayed with the Dual-Luciferase Reporter Assay System
(Promega).
Electron microscopy. HUVECs were grown to conﬂuency in an eight-well glass-
bottom chamber and were ﬁxed with 2.5% glutaraldehyde in 0.1M cacodylate
buffer and processed for Epon embedding and electron microscopy according to
a standard protocol59. Transverse sections were made. Isolated particles were also
ﬁxed and processed as above. Ultrathin sections were made and analysed using
a Tecnai 12 Spirit transmission electron microscope (FEI Co.) equipped with an
Eagle 4 k 4 k charge-coupled device camera.
Western blot analyses. Western blot was performed as previously described10.
Nuclear/cytoplasm separation was performed using an NE-PER kit (Pierce). The
following antibodies have been used: NF-kBp65 (Millipore, 17–10,060; 1:1,000),
EFNB2 (GeneTex, GTX88049; 1:1,000), VEGFA (SantaCruz Biotechnology, sc-152;
1:2,000), MLC2 (Cell Signalling, 3672; 1:1,000), p-MLC2 (Ser19; Cell Signalling,
3675; 1:500), MYPT1 (Cell Signalling, 8574; 1:1,000), p-MYPT1 (Cell Signalling,
4563; 1:500), A/C Laminin (Active Motif, 39287; 1:1,000) and Tubulin (Cell
Signalling, 2148; 1:1,000).
Animal experiments. Mouse experiments are reported in accordance with the
Animal Research Report of In Vivo Experiments (ARRIVE) guidelines. Experi-
ments were performed in accordance with the Animal (Scientiﬁc Procedures) Act
(UK) 1986 prepared by the Institute of Laboratory Animal Resources and under
the auspices of UK Home Ofﬁce Project and Personal License. Experiments were
approved by the University of Bristol Ethical Review Committee. Six- to seven-
week-old-male p75KO (ref. 60; genetic background: C57BL/6J) and WT littermates
or CD-1 mice were made diabetic using streptozotocin (STZ; Sigma)3 or left
normoglycemic after STZ buffer administration alone. STZ was delivered
intraperitoneally (i.p.) for ﬁve consecutive days (40mg kg 1 in citrate buffer per
day). Fourteen days after the ﬁrst STZ injection, glycaemia at fast and glycosuria
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were measured and only those mice with glycaemia above 200mg dl 1 and overt
glycosuria entered the protocol. Absence of hyperglycaemia and glycosuria in
buffer-injected non-diabetic mice was also veriﬁed.
Three months after the onset of hyperglycaemia, unilateral hindlimb ischaemia
was surgically induced by left femoral artery occlusion. For gene transfer
experiment, mice were anaesthetized (tribromoethanol, 880mmol kg 1 i.p., Sigma)
to induce limb ischaemia using a reﬁned procedure that consists of ligation (with a
7-0 silk suture) in two points and electrocoagulation of the upper part of the left
femoral artery, but leaving the femoral vein and nerve untouched. Immediately
after, Ad.decoy503, Ad.p75, Ad.dnIKK2, Ad.miR-503 or Ad.Null
(109 plaque-forming unit) was delivered to the ischaemic adductor muscle. The
superﬁcial blood ﬂow of the ischaemic and contralateral feet was sequentially
analysed (at 30min, and 7, 14 and 21 days) by colour laser Doppler (Lisca colour
laser Doppler, Perimed, Sweden, and Moor, USA), and the ratio of blood ﬂow
between the ischaemic foot and the contralateral foot was calculated and used as an
index of % blood ﬂow recovery. At 3 and 21 days post-ischaemia, n¼ 6 mice per
group were killed for molecular biology analyses. At 21 days post-ischaemia,
adductor muscles from terminally anaesthetized mice (n¼ 6) were in situ perfused
with heparinased PBS for 1min and then with 10% buffered formalin for 5min via
a cannula inserted into the abdominal aorta in the direction of limbs. Ischaemic
and contralateral muscles were then removed, kept in 4% buffered formalin for
24 h and processed for parafﬁn embedding61.
For analysis of vascularization, muscular sections were stained as previously
described11. Brieﬂy, sections were incubated overnight at 4 C with Alexa 488-
conjugated isolectinB4 (Molecular Probes, I21411; 1:100) to identify ECs and
Cy3-conjugated a-vascular smooth actin (Sigma-Aldrich, C6198; 1:100) to
recognize vascular smooth muscle cells (which are part of the arteriole walls). Slides
were observed under a ﬂuorescence microscope (Olympus CX41, Olympus). High-
power ﬁelds were captured (at  400) and the number of capillaries and arterioles
per ﬁeld were counted. At least 30 randomly chosen ﬁelds were evaluated.
Arterioles were recognized from venules by their morphology. In fact, arterioles
have a lumen that is circular or elliptical and well opened by the perfusion/ﬁxation.
Moreover, arterioles have one or more continuous layers of vascular smooth
muscle cells in the tunica media. Capillaries can be also identiﬁed by this staining
as being the small vessels composed by one or two ECs stained by lectin, but
missing vascular smooth muscle cells. Capillary and arteriole densities were
expressed as number of vessels per mm2 of muscular sections.
Isolation of ECs and pericytes from mouse ischaemic limb muscles. Adductor
muscles at 3 days post-ischaemia induction in diabetic and non-diabetic mice were
rinsed and digested with collagenase II (Worthington) plus DNase I (Sigma) using
gentleMACS Dissociator, following the manufacturer’s protocol. Next, ECs and
pericytes were immunomagnetic sorted using CD31 or NG2 antibodies, respec-
tively (Miltenyi Biotech), as reported in ref. 62. Purity of cell preparations was
analysed by ﬂow cytometry using CD31-FITC (Miltenyi, 130-102-970, 1:50) and
NG2-PE (eBioscience, 8012-6504-120, 1:50) antibodies.
Permeability assays. Evans Blue (0.5% ; Sigma) was injected into the tail vein and
allowed to circulate for 30min. The mice were then killed, blood was drained and
the adductor group muscle was excised and dried at 55 C. Evans Blue (Sigma) in
tissues was extracted with formamide for 24 h at 55 C, and its ﬂuorescence at
610 nm was measured by a ﬂuorescent reader (Bio-Tek)63.
miRNA in situ hybridization. For the detection of miR-503 in mouse hindlimb
muscle, sections were rehydrated in histoclear and graded concentrations of
ethanol. Slides were then boiled for 10min within 10mM sodium citrate pH 6.0,
cooled to room temperature (RT), incubated with 10 mgml 1 proteinase K at
37 C for 20min and ﬁxed in 4% paraformaldehyde (PFA) for 10min at RT.
Endogenous peroxidases were blocked by incubation with 3% H2O2 in H2O. Then,
slides were incubated with hybridization buffer (50% formamide, 4 SSC, 2.5
Denhadrt’s solution, 2.5mgml 1 salmon DNA, 0.6mgml 1 yeast tRNA, 0.025%
SDS and 0.1% blocking reagent) at 60 C for 1 h followed by a 60-C overnight
incubation with 40 nM miR-503 or scramble miRCURY LNA Detection probe, 50-
DIG labelled (Exiqon) in the same buffer. Melting temperatures were 61 and 78 C.
Immunodetection was performed by blocking the sections in 1% blocking reagent
in PBS and 10% normal goat serum for 1 h at RT, followed by an overnight
incubation at 4 C with an anti-DIG-POD antibody (Roche Applied Science)
diluted 1:400. Slides were then incubated with TSA-plus ﬂuorescein isothiocyanate
for 10min at RT to detect miR-503. Detection of isolectin-B4 (Molecular Probes,
I2141, 1:100) and NG2 (Abcam, ab81104; 1:100) was subsequently performed using
AlexaFluor 633 (Molecular Probes, 1:500) or AlexaFluore568 (Molecular Probes,
1:500) secondary antibody.
Immunohistochemistry. Samples were ﬁxed in 4% formalin, embedded in
parafﬁn wax and sectioned for histological staining. Sections were incubated
overnight at 4 C with p75NTR (Millipore, 07–476; 1:100) and NG2 antibody
(Abcam, ab81104; 1:100). Capillary and arteriole densities were determined using
ﬂuorescent microscopy on sections stained with Alexa 488-conjugated isolectin-B4
(Molecular Probes, I2141, 1:100 ) and Cy3-conjugated a-vascular smooth actin
(Sigma, C6198, 1:200).
Statistical analysis. Comparisons between different conditions were assessed
using two-tailed Student’s t-test. If the normality test failed, the Mann–Whitney
test was performed. Necrotic toe endopoint was analysed using Cochran–Armitage
trend test. Differences among groups were elicited using analysis of variance
followed by Bonferroni post hoc analyses as appropriate. Continuous data are
expressed as mean±s.e.m. of three independent experiments, each performed in
triplicate or quintuplicate. P valueo0.05 was considered statistically signiﬁcant.
Analyses were performed using GraphPad Prism v5.0.
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